Do You Need a Clinical Trial to Try Psychedelic Therapy?

Do You Have to Join a Clinical Trial to Try Psychedelic Therapy?

You do not need to join a research study to experience the benefits of legal psychedelic therapy in the United States. The confusion is understandable, since press coverage tends to focus on investigational compounds, but ketamine has been in clinical use since the 1970s.

The landscape of psychedelic medicine is divided into distinct regulatory categories. Ketamine and esketamine are broadly legally available in the U.S. for mental health, while substances like psilocybin and MDMA remain investigational at the federal level, though state-level initiatives are beginning to expand access.

Whether you need a study depends on which substance you are after. For ketamine-based options, you can work directly with a licensed provider today. For other substances, a research protocol remains the primary legal avenue.

• Legally prescribable now: Ketamine is available off-label, and esketamine is approved for treatment-resistant depression.
• State-regulated programs: Psilocybin is accessible through licensed facilitators in Oregon and Colorado.
• Research enrollment required: Psilocybin and MDMA remain restricted to research settings at the federal level.

Which Psychedelics Still Require a Clinical Trial (and Which Don't)

The legal status of psychedelic therapy in the United States is determined by a combination of federal drug schedules and state-level legislation. Navigating these pathways requires understanding how different substances are classified by regulatory bodies.

Ketamine is a Schedule III controlled substance that is FDA-approved as an anesthetic. It is legally prescribed off-label by licensed providers to address depression, anxiety, and PTSD. You can access this treatment through specialized clinics or supervised at-home programs.

Esketamine is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation. Patients must receive this medication in a certified medical office under direct supervision. No research study enrollment is required to access this option.

Psilocybin remains a Schedule I substance under federal law, so access is generally limited to registered psilocybin clinical trials. However, Oregon and Colorado have established state-regulated programs that allow adults to access psilocybin services without a federal trial. Outside of these state-level frameworks, joining a research study is the only legal option.

MDMA is currently classified as an investigational drug for mental health applications. The FDA declined to approve MDMA-assisted therapy for PTSD in 2024, citing a need for additional safety and efficacy data. Legal access to MDMA therapy therefore runs through study enrollment only.

If you want to begin treatment immediately, ketamine and esketamine are the only options available nationwide without a trial.

Ketamine and Esketamine Therapy: Legal Psychedelic Care Available Now

Providers use ketamine as a legal, accessible form of psychedelic therapy for depression, along with anxiety disorders, PTSD, grief, and burnout. Unlike traditional antidepressants that target serotonin, ketamine temporarily modulates neural communication and adjusts signaling in the glutamate system. Because it works through glutamate pathways, ketamine encourages neuroplasticity, helping the brain form new pathways and break rigid patterns of thinking.

You can receive ketamine through intravenous infusion clinics or through defined treatment frameworks at home. Esketamine requires in-office administration due to federal safety regulations. For at-home ketamine, a licensed prescriber conducts a thorough medical screening before dispensing the medicine.

Mindbloom offers a clinician-supervised at-home program that combines sublingual or subcutaneous ketamine with professional support. The program includes provider consults, guide coaching, custom soundscapes, and integration tools. A peer treatment monitor must be present during every session to ensure safety.

While psilocybin-assisted therapy remains restricted to research studies or specific states, ketamine is available to eligible individuals nationwide, under professional supervision and without the administrative hurdles of study enrollment.

How Ketamine Compares to Psilocybin and MDMA in the Research

Ketamine has the deepest evidence base in the field of psychedelic therapy, with depression-specific research dating back to 2000.³ Mindbloom's peer-reviewed data covers both routes it offers, with consistent results. In a sublingual study of 11,441 clients, 89% reported symptom improvement, 56.4% met criteria for treatment response, and 28.1% reached remission.¹ A 2026 at-home subcutaneous study showed a comparable 56.6% response and 27.7% remission⁴ — both in line with, or slightly above, published in-clinic IV ketamine outcomes.⁵

Psilocybin is still undergoing evaluation in Phase 2 and Phase 3 trials. The largest and most rigorously controlled trials report roughly 37% to 42% response rates and about 25% to 29% remission rates on standard depression scales.^6,7 Smaller trials have reported higher response rates — one 24-participant randomized trial found 71% response at four weeks — but on far smaller samples.¹²

MDMA was historically studied primarily for PTSD, with depression measured only as a secondary outcome (Mitchell et al., 2021).⁸ That changed in 2025, when a small, open-label proof-of-principle study became the first to evaluate MDMA-assisted therapy as a primary treatment for major depressive disorder, though with only 12 participants (Kvam et al., 2025).¹¹

For context outside the psychedelic class: SSRIs report 56% to 68% response but take four to six weeks to work,⁹ and talk therapy reports comparable rates over months of sessions.¹⁰ Ketamine's response sits in a similar range, but relief is often felt within hours or days.

What sets ketamine apart in this landscape is the maturity and scale of its evidence base: outcomes measured across tens of thousands of real-world patients, versus the dozens to low hundreds in the largest psilocybin trials.

• Ketamine: 89% of sublingual clients reported symptom improvement, with a 56.4% response rate and 28.1% remission rate in a study of 11,441 Mindbloom clients.¹
• Psilocybin (large trials): Approximately 37% to 42% response rates and 25% to 29% remission rates.^6,7
• Psilocybin (small trials): Up to 71% response in a 24-participant randomized trial.¹²
• MDMA: Historically a secondary outcome in PTSD trials;⁸ now the subject of one small (n=12), open-label proof-of-principle study as a primary depression treatment.¹¹

When You'd Actually Need to Join a Clinical Trial

Because psilocybin and MDMA are not yet FDA-approved, a registered research study is the only federally legal pathway to either one outside Oregon and Colorado.

Research studies move through three phases, each evaluating a different aspect of safety and effectiveness.

• Phase 1: Safety and dosing in a small group of participants.
• Phase 2: Efficacy and side effects in a larger group.
• Phase 3: Large-scale confirmation of effectiveness and monitoring of adverse reactions.

Participating in a trial involves strict eligibility criteria and a rigorous screening process. Some trials use a double-blind design, meaning you might receive a placebo instead of the active substance.

Expanded access, sometimes called compassionate use, is a separate FDA pathway that allows access to investigational drugs outside of trials in certain circumstances. However, it is rare and not widely available for psychedelics currently.

While registered research studies are essential for scientific progress, they are not the only option for individuals seeking immediate mental health support. If you prefer to begin treatment without the uncertainty of trial enrollment, ketamine therapy is available today.

How to Start Psychedelic Therapy Today

You can begin legal psychedelic therapy today by scheduling an evaluation with a licensed prescriber, no referral or study enrollment needed.

Programs run in blocks of 6, 12, or 18 sessions. The screening described earlier covers medical history, current medications, mental health symptoms, and treatment goals, and produces a personalized care plan.

Screening exists because ketamine is not appropriate for everyone; see the safety information below for specific contraindications.

If approved, sessions take place at home with your peer treatment monitor present, as described above. Beyond the consults and coaching already described, the program adds Group Integration Circles and access to the Mindbloom app.

Mindbloom's clinically managed at-home ketamine therapy starts at $165 per guided session for an eighteen-session program, which is billed in monthly installments of $330 over nine months for a total of $2,970. For a six-session program, the cost is $215 per session, billed as $430 per month over three months for a total of $1,290. Returning clients benefit from preferred pricing, paying as little as $129 per session for an eighteen-session program, billed as $258 per month over nine months.

In the 11,441-client study, 89% of participants reported symptom improvement, and onset is often noticeable within hours or days of the first session.¹ More durable and cumulative benefits typically develop over a series of sessions, supported by integration practices.

1. Select a program (6, 12, or 18 sessions) based on your goals.
2. Complete a medical evaluation with a licensed Mindbloom provider.
3. Receive your treatment plan and Bloombox with session essentials.
4. Begin at-home sessions with your peer treatment monitor present.
5. Continue with guide coaching and integration support throughout.

Taking the first step toward healing does not require waiting for regulatory changes. You can book your breakthrough today to explore whether this treatment is right for you.

Book My Breakthrough